Treda (Bismuth Subsalicylate) Dosing for a 9-Year-Old, 58 lb Child
The appropriate dose of bismuth subsalicylate for this 9-year-old child (26 kg) is 100 mg/kg/day divided into multiple doses (typically 4-5 times daily), which equals approximately 2,600 mg total daily dose, or roughly 525 mg (one adult tablet or 30 mL of regular-strength liquid) given 5 times per day for up to 5 days.
Dosing Rationale
The evidence base for pediatric bismuth subsalicylate dosing comes primarily from research studies in acute diarrhea, where 100 mg/kg/day has been the most extensively studied and validated regimen 1, 2, 3, 4. This translates to:
- Daily total: 2,600 mg (for a 26 kg child)
- Per dose: 520 mg given 5 times daily
- Practical dosing: 525 mg (two 262.5 mg chewable tablets OR 30 mL regular-strength liquid) five times daily
- Duration: Up to 5 days
Alternative Dosing Considerations
Some studies have used 150 mg/kg/day (approximately 3,900 mg daily for this child), but this higher dose showed no additional clinical benefit over 100 mg/kg/day 2. The 100 mg/kg/day regimen is preferred as it provides equivalent efficacy with lower salicylate exposure.
For children over 10 years, some protocols use 262 mg four times daily 5, but for a 9-year-old, weight-based dosing at 100 mg/kg/day remains more appropriate.
Safety Profile
Bismuth subsalicylate has demonstrated excellent safety in pediatric studies at these doses:
- Blood bismuth and serum salicylate levels remained well below toxic thresholds in all studies 2, 3, 4
- Maximum mean serum salicylate occurred on day 3 of treatment 4
- No adverse reactions were reported in controlled trials 2, 3
- Treatment duration should not exceed 5 days to minimize salicylate accumulation
Critical Safety Warnings
Reye Syndrome Risk: Bismuth subsalicylate contains salicylate and should be avoided in children with suspected viral infections (influenza, varicella, or other viral illnesses) due to the association between salicylates and Reye syndrome 5, 6. This is the most important contraindication.
Do not use if:
- Child has or recently had influenza, chickenpox, or other viral illness
- Child is taking other salicylate-containing medications
- Child has bleeding disorders or is on anticoagulants
- Child has known salicylate allergy
Clinical Context
While bismuth subsalicylate has proven efficacy in shortening diarrhea duration (reducing hospital stay from 8.5 to 6.9 days in one study 3), it is not routinely recommended as first-line therapy for pediatric diarrhea 6. The primary treatment remains oral rehydration therapy with early feeding. Bismuth subsalicylate serves as an adjunctive therapy when:
- Diarrhea is severe or prolonged
- Viral illness has been ruled out
- Standard rehydration measures need augmentation
Monitor for darkening of tongue/stool (benign and expected) and discontinue if any signs of salicylate toxicity develop (tinnitus, hyperventilation, altered mental status).